Stock Analysis

Tarsons Products Second Quarter 2025 Earnings: Revenues Beat Expectations

NSEI:TARSONS
Source: Shutterstock

Tarsons Products (NSE:TARSONS) Second Quarter 2025 Results

Key Financial Results

  • Revenue: ₹1.08b (up 62% from 2Q 2024).
  • Net income: ₹102.9m (down 20% from 2Q 2024).
  • Profit margin: 9.6% (down from 19% in 2Q 2024). The decrease in margin was driven by higher expenses.
earnings-and-revenue-growth
NSEI:TARSONS Earnings and Revenue Growth November 9th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Tarsons Products Revenues Beat Expectations

Revenue exceeded analyst estimates by 8.1%.

Looking ahead, revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Life Sciences industry in India.

Performance of the Indian Life Sciences industry.

The company's shares are up 7.2% from a week ago.

Risk Analysis

Before we wrap up, we've discovered 3 warning signs for Tarsons Products that you should be aware of.

Valuation is complex, but we're here to simplify it.

Discover if Tarsons Products might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.